Home
Search
Agriculture & Environment

Addressing Climate Change

There are more than 5 trillion pieces of plastic floating in our oceans. The U.S. transportation sector leads all other sectors in greenhouse gas emissions. Diseases that thrive in hot weather are killing important staple crops. Our reliance on products derived from fossil fuels is harming our planet.

Climate change is real but through biotechnology, we can meet these challenges head-on by making the same reliable plastics, foods, and fuels with less environmental impact.

Dr Michelle Climate
Biotech Solutions for Climate Report
Biotech Solutions for Climate Executive Summary
More on BIO's Global Climate Leadership
Latest from BIO's Experts...
GMOS and Gene Editing—Nothing to Be Afraid Of
GMOS and Gene Editing—Nothing to Be Afraid Of
Learn more
Escaping the Food Allergy Prison
Escaping the Food Allergy Prison
Learn more
Car Free Day
Car-Free Day: Could Biotech Make It a Thing of the Past?
Learn more
Bananas
Improving Food Systems: The Case of the Banana
Learn more
roots Trees Alone Can’t Solve Our Climate Issues
Trees Alone Can’t Solve Our Climate Issues
Learn more
Press Releases
Browse all Press Releases
Organizations Focused on Fight Against Superbugs Celebrate Reintroduction of the PASTEUR Act
April 27, 2023
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year  Today, five prominent national organizations — the Biotechnology Innovation Organization, the Cystic Fibrosis Foundation, the Infectious Diseases Society of America, the Partnership to…
Call for Sessions for BIO's Impact Ag & Environment Conference
April 27, 2023
BIO’s Impact Ag & Environment Conference, Sept. 19-20, 2023, in Raleigh, N.C., is an opportunity for companies and non-governmental organizations working across agriculture, bioprocessing, and climate adaptation/mitigation to connect and collaborate. With sessions on climate change and food…
BIO to redouble efforts to ensure regulatory decision-making is "grounded in scientific and medical expertise"
April 21, 2023
The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid.  BIO interim President and CEO, Rachel King, made the following…
Good Day BIO Newsletter
Subscribe to GoodDay BIO

Receive the best resource for the biotech industry with Good Day BIO, the only daily newsletter at the intersection of biotech, politics and policy. 

Subscribe

A Timeline of Modernizing Food and Farm Biotech Laws...

plants
2019: USDA Announces SECURE Rule

To provide transparency to consumers, BIO advocates for the agency to require developers to notify them when new plants are brought to market,

Cabinet
2019: Executive Order to Modernize Biotech Framework

President Trump directs USDA, EPA, and FDA to align existing biotech regulations with actual risk and to grow pubic confidence in biotech to benefit our food, health, and planet.

Trump Rural
2017: Trump Administration Establishes Rural Prosperity Task Force

The task force includes biotechnology as part of its recommendations to the government on how to strengthen rural economies.

Obama produce
2017: Obama Administration Updates Biotech Laws

To keep up with 21st-century innovations USDA and FDA begin updating definitions and enforcement of biotech plants and animals. 

obama flag
2012: National Bioeconomy Blueprint Unveiled

The blueprint is a comprehensive vision to strengthen America's economy through technology and science, and spotlights agricultural biotechnology.

Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
BIO COMMENT LETTER OMB Race and Ethnicity OMB 2023
April 12, 2023
BIO provided detailed comments to the Office of Management and Budget (OMB) regarding the Initial Proposals For Updating OMB’s Race and Ethnicity Statistical Standards.
BIO Statement for House Financial Services Subcommittee on Capital Markets Hearing: “A Roadmap for Growth: Reforms to Encourage Capital Formation and Investment Opportunities for All Americans”
April 23, 2023
BIO’s Chief Advocacy Officer Nick Shipley presents comments to the Committee as it considers reforms to encourage capital formation and investment opportunities for all Americans.
BIO Comments to Centers for Medicare & Medicaid Services (CMS) on Medicare Drug Price Negotiation Program: Initial Memorandum, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026
April 14, 2023
BIO comments on the initial guidance regarding the Drug Price Negotiation Program (Negotiation Program) under the Inflation Reduction Act of 2022 issued by CMS on March 15, 2023 (Initial Guidance)